Know Cancer

forgot password

Phase I Study of Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

Phase 1
18 Years
Open (Enrolling)
Neuroendocrine Tumor, Carcinoid Tumor, Pancreatic Neuroendocrine Tumor

Thank you

Trial Information

Phase I Study of Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

- Since we are looking for the highest dose of the study drug that can be administered
safely without severe or unmanageable side effects in participants that have
neuroendocrine tumors, not everyone who participates in this research study will
receive the same dose of the study drug. The dose the participant will be given will
depend on the number of participants who have been enrolled in the study.

- Each treatment cycle lasts 28 days. Participants will take RAD001 orally once a day in
the morning. Participants will take sorafenib orally twice daily.

- Initially participants will come to the clinic every other week. At these visits
bloodwork will be taken to monitor the participants health. Every 2 months of
treatment, participants will have a CT scan or MRI done to see how the medication is

- Participants will remain on this research study as long as they continue to benefit
from the study medications.

Inclusion Criteria:

- Locally unresectable or metastatic neuroendocrine tumor (carcinoid tumor or
pancreatic neuroendocrine tumor). Patients must have confirmed low-grade or
intermediate-grade neuroendocrine carcinoma. Patients with poorly differentiated
neuroendocrine carcinoma, high-grade neuroendocrine carcinoma, adenocarcinoid, goblet
cell carcinoid, and small cell carcinoma are not eligible.

- 18 years of age or older

- Minimum of four weeks since any major surgery, completion of radiation, or completion
of all prior systemic anticancer therapy. Bevacizumab should not have been received
within the prior 6 weeks.

- Prior treatment with chemotherapy is allowed. Patients may not have received prior
therapy with RAD001 or sorafenib. There is no limit to the number of prior
chemotherapy regimens a patient may have received. Patients may receive concomitant
therapy with somatostatin analogs.

- ECOG performance status 0 or 1

- Life expectancy 12 weeks or more

- Adequate bone marrow, liver and renal function as outlined in the protocol

- Fasting serum glycerides and fasting triglycerides as outlined in the protocol

- INR < 1.5 or PT/PTT within normal limits. Patients receiving anti-coagulation
treatment with an agent such as warfarin or heparin may be allowed to participate.

- Women of child bearing potential must have a negative serum pregnancy test within 14
days of the administration of the first study treatment. Women must not be

Exclusion Criteria:

- Prior treatment with cytotoxic chemotherapy, radiation, immunotherapy, or any
investigational drug within the preceding 4 weeks. Bevacizumab should not have been
received within the prior 6 weeks.

- Prior treatment with RAD001 or sorafenib

- Patients who have undergone major surgery within 4 weeks prior to study enrollment.

- Chronic treatment with systemic steroids or another immunosuppressive agent

- Patients should not receive immunization with attenuated live vaccines during study
period or within 1 week of study entry.

- Known brain metastases

- Patients with prior or concurrent malignancy except for the following: adequately
treated basal cell or squamous cell skin cancer, or other adequately treated in situ
cancer, or any other cancer from which the patient has been disease free for five

- Patients with uncontrolled diabetes mellitis or a fasting plasma glucose > 1.5 ULN

- Patients who have congestive heart failure (NHYA Class III or IV), unstable angina,
sustained ventricular tachycardia, ventricular fibrillation, clinically significant
bradycardia, advanced heart block or a history of acute myocardial infarction within
the six months preceding enrollment. No new onset angina within 3 months preceding
enrollment. No cardiac ventricular arrhythmia requiring antiarrhythmic therapy.

- Uncontrolled hypertension

- Active clinically serious infection

- Serious non-healing wound, ulcer, or bone fracture

- Evidence of history of bleeding diathesis or coagulopathy

- Patients with the presence of active or suspected acute or chronic uncontrolled
infection or with a history of immunocompromise, including a positive HIV test result

- Patients who have any severe and/or uncontrolled medical conditions or other
conditions what could affect their participation in the study

- Use of St. John's Wort or rifampin (rifampicin)

- Patients with a known or suspected hypersensitivity to sorafenib, RAD001 or other
rapamycins or to its excipients

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To determine the maximum tolerated dose (MTD) for sorafenib in combination with RAD001 in patients with advanced neuroendocrine tumors.

Outcome Time Frame:

2 years

Safety Issue:


Principal Investigator

Jennifer Chan, MD, MPH

Investigator Role:

Principal Investigator

Investigator Affiliation:

Dana-Farber Cancer Institute


United States: Institutional Review Board

Study ID:




Start Date:

July 2009

Completion Date:

Related Keywords:

  • Neuroendocrine Tumor
  • Carcinoid Tumor
  • Pancreatic Neuroendocrine Tumor
  • sorafenib
  • RAD001
  • Carcinoid Tumor
  • Neuroendocrine Tumors
  • Adenoma, Islet Cell



Dana-Farber Cancer Institute Boston, Massachusetts  02115